Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris

PHASE1CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions
Acne Vulgaris
Interventions
DRUG

AGN-190168 Formulation 1

AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

DRUG

AGN-190168 Formulation 2

AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

DRUG

tazarotene gel 0.1%

Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

DRUG

tazarotene cream 0.1%

Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.

Trial Locations (1)

Unknown

College Station

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY